Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review

por Hayslip, John, Montero, Alberto
Publicado 2006

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

por Badin, Firas, Hayslip, John
Publicado 2010

Validated LC–MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application

por Ahmed, Tamer A., Horn, Jamie, Hayslip, John, Leggas, Markos
Publicado 2012

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

por Hayslip, John, Chaudhary, Uzair, Green, Mark, Meyer, Mario, Dunder, Steven, Sherman, Carol, Salzer, Shanta, Kraft, Andrew, Montero, Alberto J
Publicado 2007

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

por Brackman, Deanna, Eckert, Doerthe, Menon, Rajeev, Salem, Ahmed Hamed, Potluri, Jalaja, Smith, B. Douglas, Wei, Andrew H., Hayslip, John, Miles, Dale, Mensing, Sven, Gopalakrishnan, Sathej, Zha, Jiuhong
Publicado 2022

Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna—A Randomized, Cross-Over Clinical Study

por Hayslip, John, Dressler, Emily V., Weiss, Heidi, Taylor, Tammy J., Chambers, Mara, Noel, Teresa, Miriyala, Sumitra, Keeney, Jeriel T. R., Ren, Xiaojia, Sultana, Rukhsana, Vore, Mary, Butterfield, D. Allan, St Clair, Daret, Moscow, Jeffrey A.
Publicado 2015

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

por Wei, Andrew H., Strickland, Stephen A., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Walter, Roland B., Enjeti, Anoop, Tiong, Ing Soo, Savona, Michael, Lee, Sangmin, Chyla, Brenda, Popovic, Relja, Salem, Ahmed Hamed, Agarwal, Suresh, Xu, Tu, Fakouhi, Kaffa M., Humerickhouse, Rod, Hong, Wan-Jen, Hayslip, John, Roboz, Gail J.
Publicado 2019

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

por Wei, Andrew H., Panayiotidis, Panayiotis, Montesinos, Pau, Laribi, Kamel, Ivanov, Vladimir, Kim, Inho, Novak, Jan, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Bergeron, Julie, Ting, Stephen B., Hou, Jing-Zhou, Anagnostopoulos, Achilles, McDonald, Andrew, Murthy, Vidhya, Yamauchi, Takahiro, Wang, Jianxiang, Chyla, Brenda, Sun, Yan, Jiang, Qi, Mendes, Wellington, Hayslip, John, DiNardo, Courtney D.
Publicado 2021

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

por Wei, Andrew H., Panayiotidis, Panayiotis, Montesinos, Pau, Laribi, Kamel, Ivanov, Vladimir, Kim, Inho, Novak, Jan, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Bergeron, Julie, Ting, Stephen B., Hou, Jing-Zhou, Anagnostopoulos, Achilles, McDonald, Andrew, Murthy, Vidhya, Yamauchi, Takahiro, Wang, Jianxiang, Chyla, Brenda, Sun, Yan, Jiang, Qi, Mendes, Wellington, Hayslip, John, DiNardo, Courtney D.
Publicado 2021